Nutri/System "phen/Pro" weight-loss campaign draws objection from Lilly.
Executive Summary
NUTRI/SYSTEM "PHEN/PRO" PROMOTION DRAWS OBJECTION FROM LILLY in a Sept. 22 letter to the weight-loss center network. The letter maintains that Nutri/System has been conducting a promotional campaign regarding the use of Lilly's antidepressant Prozac (fluoxetine) in combination with phentermine that includes direct-to-consumer television ads. "This campaign has occurred without the agreement, cooperation or knowledge of Lilly," the letter declares.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth